Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: balanced salt solution Clear all
Completed No phase listed Observational

Resistance to Antibiotics in Patients Receiving Eye Injections

NCT02126423
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Conjunctival and nasopharyngeal swabs
Other
Lead sponsor
Prism Vision Group
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Sep 3, 2026, 2:31 AM EDT
Recruiting Phase 2 Interventional

Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye

NCT07413172
View directory record Official record
Conditions
Dry Eye, Eye Diseases, Eyes Dry Chronic
Interventions
Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate), Biological - Autologous Serum Tears (50% Autologous Serum Tears + Balanced Saline Solution (BSS), Standard of Care (SOC) Treatment
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Hypertonic Saline in Posterior Spinal Fusion

NCT06822374
View directory record Official record
Conditions
Scoliosis Idiopathic, Scoliosis;Congenital
Interventions
Normosol-R, buffered 2% hypertonic saline
Drug
Lead sponsor
Joseph D. Tobias
Other
Eligibility
10 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

NCT00853073
View directory record Official record
Conditions
Glaucoma
Interventions
bevacizumab, balanced salt solution
Drug · Other
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Boluses of Ringer's in Surgical Kids (BRiSK Study)

NCT05285371
View directory record Official record
Conditions
Dehydration in Children, Fluid Therapy
Interventions
Urinalysis (UA), Complete Metabolic Panel (CMP), Glucose Stick Test (d-Stick), Medical Chart Review
Diagnostic Test · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 21 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery

NCT01115517
View directory record Official record
Conditions
Pterygium
Interventions
Bevacizumab, Mitomycin C
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 3 Interventional

Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction

NCT00245271
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
17 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Redwood City, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Not applicable Interventional Results available

Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)

NCT02547779
View directory record Official record
Conditions
Critical Illness, Acute Kidney Injury
Interventions
0.9% Saline, Physiologically-balanced isotonic crystalloid
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
10,421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions

NCT00660166
View directory record Official record
Conditions
Lymphoma, Myeloma, Leukemia
Interventions
NK-Cell Infusion
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
13 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Topical Naloxone to Diagnose Ocular Pain

NCT04454281
View directory record Official record
Conditions
Dry Eye Syndromes, Neuropathic Pain
Interventions
Naloxone Hydrochloride 0.4 MG/ML
Drug
Lead sponsor
Seema Capoor
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

NCT01848340
View directory record Official record
Conditions
HIV-associated Lipodystrophy Syndrome
Interventions
GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

NCT01193127
View directory record Official record
Conditions
Cataract
Interventions
OMS302 Solution, OMS302 Mydriatic Solution, OMS302 Anti-inflammatory Solution, Balanced Salt Solution (BSS) Solution
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Chandler, Arizona • Glendale, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Sep 3, 2026, 2:31 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Anesthetic Impregnated Bandage Soft Contact Lens (BSCL) in Pain Management After Photorefractive Keratectomy (PRK)

NCT04283331
View directory record Official record
Conditions
Myopia, Hypermetropia, Refractive Errors, Astigmatism
Interventions
Proparacaine Ophthalmic
Drug
Lead sponsor
Beeran Meghpara, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional

Novel Drug Delivery Technique Via Retroject Device

NCT02051946
View directory record Official record
Conditions
Glaucoma
Interventions
Retroject Device, ethacrynic acid injection, balanced salt solution
Device · Drug
Lead sponsor
Molly Walsh
Other
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 3, 2026, 2:31 AM EDT
Recruiting Phase 4 Interventional

Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?

NCT05663684
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2 Interventional

A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy

NCT02435862
View directory record Official record
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
1.0mg Luminate®, 2.0mg Luminate®, 3.0mg Luminate®, Balanced Salt Solution for intravitreal injection in 0.10cc
Drug · Other
Lead sponsor
Allegro Ophthalmics, LLC
Industry
Eligibility
45 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Mountain View, California • Orange, California • New London, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 3, 2026, 2:31 AM EDT
Terminated Phase 4 Interventional Results available

Does Topical Ophthalmic Anesthetic Prior to Probing and Irrigation Decrease Pain?

NCT04229771
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

NCT00853905
View directory record Official record
Conditions
Glaucoma
Interventions
Triesence, balanced salt solution BSS
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 3, 2026, 2:31 AM EDT
Recruiting Phase 3 Interventional

Saline Versus Balanced Crystalloid in Traumatic Brain Injury

NCT06953674
View directory record Official record
Conditions
Traumatic Brain Injury (TBI) Patients
Interventions
Normal Saline (0.9% NaCl), balanced crystalloid
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

NCT02153476
View directory record Official record
Conditions
Symptomatic Focal Vitreomacular Adhesion
Interventions
2.0mg of ALG-1001, Balanced Salt Solution
Drug
Lead sponsor
Allegro Ophthalmics, LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • Santa Barbara, California • Winter Haven, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01579565
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

NCT02132312
View directory record Official record
Conditions
Unilateral Cataract Extraction, Congenital Cataract
Interventions
OMS302, Phenylephrine HCl
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
1 Day to 47 Months
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 3, 2026, 2:31 AM EDT
Not yet recruiting Phase 3 Interventional

RB-PDT for Fusarium Keratitis: The LUMIERE Study

NCT07743489
View directory record Official record
Conditions
Fusarium Keratitis
Interventions
Rose Bengal Photodynamic Therapy, Sham RB-PDT
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 3, 2026, 2:31 AM EDT